...
首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Preliminary experience with direct percutaneous arterial embolisation combined with radiofrequency ablation for hypervascular HCC
【24h】

Preliminary experience with direct percutaneous arterial embolisation combined with radiofrequency ablation for hypervascular HCC

机译:直接经皮动脉栓塞结合射频消融治疗高血管HCC的初步经验

获取原文

摘要

Objective: The purpose of this study was to evaluate the outcomes of a novel technique consisting of ultrasound-guided percutaneous arterial embolisation (PAE) of the tumour-feeding artery before radiofrequency ablation (RFA) for hypervascular hepatocellular carcinoma (HCC). Methods: Twenty-three HCC patients with hypervascular tumours who were non-TACE candidates were enrolled in the study. The mean size of the tumours was 4.6?±?1.2?cm (3.2–6.0?cm). PAE was performed using 20-gauge catheter needles under greyscale and colour ultrasound guidance. Regular follow-up was performed to evaluate the outcomes and safety of this novel method. Results: Post-PAE colour Doppler ultrasound revealed an immediate embolising effect in 29 feeding arteries, including 21 arteries that became invisible (72.4%) and 8 arteries that exhibited reduced flow velocity (27.6%). Based on the one-month enhanced CT/MRI, complete necrosis was achieved in 24 of 25 tumours (96.0%). The mean follow-up period was 42.7?±?9.8?months. Local tumour recurrence was observed in 3 tumours (12.0%), and new intrahepatic tumours developed in 9 patients (39.1%). The probabilities of overall survival at 1, 3, 5 and 10?years were 77.3%, 40.0%, 25.0% and 18.8%, respectively. No major complications occurred in this group. Conclusions: The PAE method could help effectively to reduce or inhibit the blood supply of HCC. RFA followed by PAE treatment achieved 25.0% 5-year survival with no major complications. As a minimally invasive approach, PAE may provide a novel local therapy for hypervascular HCC patients who are non-TACE candidates.
机译:目的:本研究的目的是评估一种新技术的结果,该技术由超声引导的射频消融(RFA)之前的肿瘤供血动脉经皮动脉栓塞(PAE)用于高血管肝细胞癌(HCC)。方法:选择非TACE候选者的23例HCC伴有血管肿瘤的患者纳入研究。肿瘤的平均大小为4.6?±?1.2?cm(3.2–6.0?cm)。在灰度和彩色超声引导下,使用20号导管针进行PAE。定期进行随访以评估这种新方法的结果和安全性。结果:PAE后彩色多普勒超声显示29颗进食动脉具有立即栓塞效果,其中21根变得不可见(72.4%),8根流速降低(27.6%)。根据为期一个月的增强型CT / MRI,在25个肿瘤中的24个(96.0%)中完全坏死。平均随访时间为42.7±±9.8个月。在3个肿瘤(12.0%)中观察到局部肿瘤复发,在9个患者(39.1%)中出现了新的肝内肿瘤。在1、3、5和10岁时的总体生存率分别为77.3%,40.0%,25.0%和18.8%。该组无重大并发症发生。结论:PAE法可有效减少或抑制肝癌的血液供应。 RFA继之以PAE治疗可达到25.0%的5年生存率,无重大并发症。作为一种微创方法,PAE可以为非TACE候选者的高血管HCC患者提供一种新颖的局部疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号